Henoch-Schönlein purpura medical therapy: Difference between revisions

	Henoch-Schönlein purpura Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Henoch-Schönlein purpura from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Henoch-Schönlein purpura medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Henoch-Schönlein purpura medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Henoch-Schönlein purpura medical therapy
CDC on Henoch-Schönlein purpura medical therapy
Henoch-Schönlein purpura medical therapy in the news
Blogs on Henoch-Schönlein purpura medical therapy
Directions to Hospitals Treating Henoch-Schönlein purpura
Risk calculators and risk factors for Henoch-Schönlein purpura medical therapy

Revision as of 01:57, 6 February 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

@@ Line 5: / Line 5: @@
 ==Overview==
 ==Medical therapy==
-Most patients do not receive therapy because of the high spontaneous recovery rate. [[Glucocorticoid|Steroids]] are generally avoided. However, if they are given early in the disease episode, the duration of symptoms may be shortened, although abdominal pain does not improve significantly. Moreover, the changes of severe kidney problems are reduced.<ref name="pmid17974746">{{cite journal |author=Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C |title=Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review |journal=Pediatrics |volume=120 |issue=5 |pages=1079–87 |year=2007 |pmid=17974746|doi=10.1542/peds.2007-0667}}</ref>
-Evidence of worsening kidney damage would normally prompt a kidney biopsy. Treatment may be indicated on the basis of the appearance of the biopsy sample; various treatments may be used, ranging from oral steroids to a combination of intravenous [[methylprednisolone]] (a potent steroid), [[cyclophosphamide]] and [[dipyridamole]] followed by prednisone. Other regimens include steroids or [[azathioprine]], and steroids or cyclophosphamide (with or without [[heparin]] and [[warfarin]]). [[Intravenous immunoglobulin]] (IVIG) is occasionally used.
 ==References==